SERPING1 and hereditary angioedema: C1-INH-HAE patients were identified in the IMS Health PharMetrics Plus claims database for the period January 2012 to December 2016 by International Classification of Diseases (ICD) 9/10 diagnosis code, and classified into “pdC1-INH” (Cinryze and Berinert) or “Other (non-C1-INH) treatment” (Firazyr and Kalbitor) groups.